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Complement neutralises invading pathogens, 
stimulates inflammatory and adaptive 
immune responses and targets non- or 
altered-self structures for clearance.  In the 
classical and lectin activation pathways it is 
initiated when complexes composed of 
separate recognition and activation 
subcomponents bind to a pathogen surface.  
Despite its apparent complexity, recognition-
mediated activation has evolved 
independently in three separate protein 
families, C1q, mannose-binding lectins 
(MBLs) and serum ficolins.  Although 
unrelated, all have bouquet-like architectures 
and associate with complement-specific serine 
proteases: MBLs and ficolins with MBL-
associated serine protease-2 (MASP-2) and 
C1q with C1r and C1s.  To examine the 
structural requirements for complement 
activation, we have created a number of novel 
MBLs in which the position and orientation of 
the MASP-binding sites have been changed.  
We have also engineered MASP-binding into 
a pulmonary-surfactant protein (SP-A), which 
has the same domain structure and 
architecture as MBL, but lacks any intrinsic 
complement activity.  The data reveal that 
complement activity is remarkably tolerant to 
changes in the size and orientation of the 
collagenous stalks of MBL, implying 
considerable rotational and conformational 
flexibility in unbound MBL.  Furthermore, 
novel complement activity is introduced 
concurrently with MASP binding in SP-A, but 
is uncontrolled and occurs even in the absence 
of a carbohydrate target.  Thus, the active 
state is default and must be inhibited in 
circulating MBLs through additional regions 
(not present in SP-A) until facilitated by 
pathogen recognition. 
 
Complement is a central part of the 
immune system that neutralises pathogens via 
antibody-dependent and -independent 
mechanisms and stimulates a variety of 
protective responses including phagocytosis, 
inflammation and adaptive immunity (1).  It is 
triggered via three routes called the classical, 
lectin and alternative pathways.  Although the 
alternative pathway is initially non-specific and 
depends on host regulatory proteins to avert 
activation on self structures, the classical and 
lectin pathways both selectively target pathogen-
associated molecular patterns via circulating 
complexes composed of recognition and 
zymogen-protease subcomponents (2).  Upon 
binding to a target, conformational changes in 
the recognition subcomponent trigger activation 
of the protease subcomponent, which in turn 
activates the downstream complement cascade.  
In the classical pathway, C1q binds to 
microorganisms, immune complexes, apoptotic 
and necrotic cells as well as amyloids to initiate 
the stepwise activation
 
of C1r and C1s.  In the 
lectin pathway, mannose-binding
 
lectin (MBL) 
and serum ficolins bind to terminal mannose-like 
epitopes or
 
N-acetyl groups on pathogens to 
activate MBL-associated
 
serine protease-2 
(MASP-2). 
Initiating complexes of the classical and 
lectin pathways have a number of structural and 
functional properties in common (2).  Although 
unrelated, recognition subcomponents have 
similar domain organizations consisting of a 
short cysteine-containing domain followed by a 
collagen-like domain, which is linked to a C-
terminal recognition domain (Fig. 1; (3)).  
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During biosynthesis, polypeptides associate into 
trimeric subunits (4), which assemble to form 
larger oligomers resembling bouquets (5, 6).  In 
C1q, the N-terminal portions of the collagenous 
stalks associate with each other and splay apart at 
a short interruption within the repeating Gly-
Xaa-Yaa sequence, called the kink.  Although 
MBL and some ficolins also possesses a kink-
like region, recent measurements have revealed 
that the stalks probably diverge nearer the N-
terminus, at the junction with the cysteine-
containing domain, and thus form spider-like 
structures rather than the classical bouquets of 
C1q (7).  Recognition subcomponents possess 
different numbers of subunits.  For example, 
human C1q is a hexamer assembled from three 
different polypeptide chains (8) and rat MBLs 
are homooligomers comprising dimers, trimers 
and tetramers of subunits (9).   
The protease subcomponents, C1r and 
C1s of the classical pathway and MASP-2 of the 
lectin pathway are homologous, and bind to the 
collagenous domains of their respective 
recognition subcomponent through Ca
2+
-
dependent interactions (10-13).  They each 
comprise two Ca
2+
-binding CUB domains 
(domain found in complement component 
C1r/C1s, Uegf, and bone morphogenic protein 
1), separated by a Ca
2+
-binding epidermal growth 
factor-like domain (EGF), followed by two 
complement-control protein (CCP) modules and 
a serine protease (SP) domain (14, 15).  C1r and 
C1s form heterotetramers (C1s-C1r-C1r-C1s) 
and MASPs are homodimers.  Although the 
stoichiometries of the resulting C1 and MBL-
MASP complexes differ, interactions between 
subcomponents are analogous, with equivalent 
contacts between the CUB domains of the 
proteases and the collagenous domains of the 
recognition subcomponents (2).  Overall, each 
C1rs tetramer presents a total of six binding sites, 
one for each of the collagenous domains of C1q 
(one site on each CUB1 of C1r and C1s and each 
CUB2 of C1r).  Each MASP-2 dimer presents 
four binding sites to MBL and ficolins (one site 
on each CUB domain). 
A number of other proteins have 
bouquet-like architectures, such as adiponectin 
(16), emilins (17) and some collectins (18), 
including pulmonary surfactant protein-A (SP-
A).  Nevertheless, only MBLs, ficolins and C1qs 
are able to activate complement.  As yet, the only 
established difference between these proteins and 
their structural analogues is their ability to bind 
to MASPs or C1rs tetramers.  The MASP-
binding site in MBLs and ficolins is 
characterised by a distinct motif within the 
collagenous domain: Hyp-Gly-Lys-Xaa-Gly-Pro, 
where Hyp is hydroxyproline and Xaa is 
generally an aliphatic residue.  Point mutations to 
this sequence disrupt MASP binding (10, 13).  
C1q also possesses a similar motif and we have 
proposed that this region forms the binding sites 
for C1r and C1s (2). 
In this manuscript, we have further 
probed the functions of the recognition 
subcomponents by examining the structural 
requirements for complement activation.  
Initially, we modified the collagenous domain of 
MBL to change the position and relative 
orientations of the MASP-binding site on the 
collagenous stalks.  The data reveal that MASP 
binding and activation are surprisingly tolerant to 
such changes, implying considerable rotational 
and conformational flexibility.  To take these 
studies further, we have engineered the MASP-
binding motif into SP-A, which also has a C-type 
lectin domain and a similar architecture to MBL, 
but cannot bind MASPs or activate complement.  
We find that MASP binding comparable to MBL 
can be engineered through just three amino acid 
substitutions to the collagenous domain of SP-A.  
The resulting proteins also activate the MASP, 
but lack the control mechanisms necessary to 
target carbohydrate surfaces selectively. 
EXPERIMENTAL PROCEDURES 
Protein Components Recombinant rat 
MBL and modified forms of rat MASP-2 were 
produced in a Chinese hamster ovary cell-
expression system and purified as described 
previously by affinity chromatography on 
mannose-Sepharose and nickel-Sepharose 
columns, respectively (9, 19).  MASP-2A is a 
catalytically inactive form of rat MASP-2 in 
which the active site serine at position 613 has 
been replaced by an alanine.  MASP-2K is a 
catalytically active form, in which the arginine 
residue at the cleavage site for zymogen 
activation (Arg
424
) has been changed to a lysine 
residue to slow down the rate of spontaneous 
autoactivation during biosynthesis. Mutant forms 
of MBL were created by PCR and expressed in 
the same way as the wild-type protein. 
Cloning and production of recombinant 
wild type and mutant SP-As The cDNA of SP-
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A isoform A1 was cloned into the polylinker of 
the eukaryotic expression vector pED-4 (20), 
which contains the dihydrofolate reductase 
cDNA as a selectable marker.  Proteins were 
produced by expression in the Chinese hamster 
ovary cell line DXB11 following amplification 
using the dihydrofolate reductase inhibitor, 
methotrexate, to a final concentration of 25 M.  
Culture media was harvested using a protocol 
that has been described previously for production 
of recombinant MBL (9, 21).  Protein was 
purified by affinity chromatography on mannose-
Sepharose columns (1 ml column for 250 mls of 
media).  Following washes with high salt (50 
mM Tris pH 7.5, containing 150 mM NaCl and 
2.5 mM CaCl2) and low salt buffers (10 mM Tris 
pH 7.5, containing 10 mM NaCl and 2.5 mM 
CaCl2) protein was eluted in 0.5 ml fractions of 
10 mM Tris pH 7.5, containing 10 mM NaCl and 
2.5 mM EDTA.  Fractions containing 
recombinant protein were identified by SDS-
polyacrylamide gel electrophoresis.  Mutations 
were introduced into to the cDNA of SP-A by 
PCR and the encoded proteins were produced in 
the same way as the wild type protein.  Although 
SP-A tolerated relatively high salt concentrations 
when bound to the Sepharose matrix, 
concentrations >10 mM caused significant 
aggregation in solution. 
 
Surface plasmon resonance  
Measurements were performed using a BIAcore 
2000 instrument (GE Healthcare) or a BioRad 
ProteOn XPR36 biosensor.  Protein ligands were 
diluted into 10 mM sodium acetate (pH 4.5 for 
MBL or pH 5.0 for SP-A), and immobilized on 
to the carboxymethylated dextran surface of
 
a 
CM5 sensor chip (GE Healthcare) or a GLM 
chip (BioRad), using amine coupling chemistry.  
Binding was measured
 
in 10 mM Tris-HCl (pH 
7.4) containing 140 mM NaCl, 2 mM CaCl2 and 
0.005% surfactant SP40,
 
at a flow rate of 25 
µl/min and at 25°C.  After injection
 
of ligand, the 
protein surface was regenerated
 
by injection of 
10 µl of 10 mM Tris-HCl buffer (pH 7.4) 
containing
 
1 M NaCl and 5 mM EDTA.  Data 
were analyzed by fitting association
 
and 
dissociation curves to Langmuir binding models 
for several
 
protein concentrations 
simultaneously, using BIAevaluation 4.1
 
software (GE Healthcare).  Increasingly complex 
models were tested
 
until a satisfactory fit to the 
data was achieved.  Apparent
 
equilibrium 
dissociation constants (KD) were calculated from
 
the ratio of the dissociation and association rate 
constants
 
(koff/kon).  MBL was immobilized on the 
chip surface rather than used as a soluble ligand, 
because it bound to the chip thereby masking 
analysis of the protein-protein interactions.  SP-
A was also immobilized because it tended to 
precipitate on the chip surface.  
 
MASP-2 activation assays Activation 
was measured by following MASP autolysis 
using a modified version of the protocol 
described previously (22).  Briefly, MASP-2K 
was mixed with wild-type or mutant MBL or SP-
A and added to a suspension of  fucose-
Sepharose (5 µl
 
of a 1:1 v/v suspension in a total 
volume of 30 µl), in
 
50 mM Tris-HCl (pH 7.5) 
containing 150 mM NaCl and 5 mM CaCl2,
 
at 
37°C with mixing.  A 1.2-fold molar excess of 
MBL or SP-A
 
was used to ensure that all the 
MASP-2K was bound to the recognition 
molecule.  The mixture was incubated at 37 °C 
with shaking and aliquots of the suspension were 
removed from the reaction
 
mix at various
 
times 
and immediately frozen on dry ice to quench the 
reaction.  Proteins were separated by SDS-
polyacrylamide gel electrophoresis under 
reducing
 
conditions and the amount of MASP 
cleaved was quantified by densitometry.  Data 
are the mean ± S.E. from at least two separate 
experiments using different protein preparations, 
unless otherwise stated. 
 
RESULTS 
 
MASP-binding and activation are 
tolerant to changes in the position and 
orientation of binding sites on MBL MASPs 
bind inside the cone created by the collagenous 
stalks of MBL and bridge up to four stalks 
simultaneously (Fig. 1; (3)).  Consequently, 
during complex formation, the binding sites on 
the MBL stalks must either face inwards or re-
orientate so that the correct collagen-CUB 
domain interactions are formed.  If the stalks are 
relatively rigid or are unable to re-orientate 
independently, any change in their position or 
alignment would lead to loss of function.  In 
order to examine the tolerance of MBL to such 
changes, we made a series of modified MBLs in 
which the collagenous domain was modified.  
Because the pitch of collagen is typically ~3.5 
residues (23), deletion or insertion of a Gly-Xaa-
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Yaa triplet would change both the position of 
each binding site and its relative orientation.  For 
example, deletion of a triplet would effectively 
rotate each collagenous stalk by ~180° as well as 
shift the position of the binding site further 
towards the N-terminus (Fig. 1).  Deletion of a 
second triplet would restore the original 
alignment but move the binding sites even 
further towards the N-terminus.  To 
accommodate all of these changes, the 
collagenous stalks would not only have to splay 
further apart (for a deletion) or move closer 
together (for an insertion), but also rotate 
independently of each other.  Thus, analysis of 
MASP binding and activation by the modified 
MBLs provides a useful probe of the 
conformational and rotational flexibility of MBL. 
Two deletion mutants were created in 
which either one or two Gly-Xaa-Yaa triplets 
were removed from the collagenous domain, thus 
moving the MASP-binding motif closer to the N-
terminus of MBL (Fig. 1).  In addition, a single 
Gly-Pro-Hyp was inserted near the kink-like 
region to move the MASP binding motif further 
towards the C-terminus.  We also made an MBL 
in which the kink-like region itself was removed 
by insertion of a proline residue to restore the 
Gly-Xaa-Yaa tandem repeats.  A previous study 
has demonstrated that the kink-like region is not 
essential for complement activation by MBL 
(24).  However, the kinetics of activation were 
not investigated in this work, so more subtle 
changes might have been missed.  Analysis of 
the purified, recombinant MBLs by SDS-
polyacrylamide gel electrophoresis under non-
reducing conditions, shown previously to be a 
sensitive indicator of MBL assembly (25), 
demonstrated that all assembled correctly during 
biosynthesis (Fig. 2). 
Initially MBLs were tested for their 
abilities to bind to MASP-2A, using surface 
plasmon resonance.  As expected, wild-type 
bound with complex kinetics compatible with the 
formation of 1:1 complexes, together with 
binding of a second MASP at relatively high 
protein concentrations (19).  The KDs were 3.7 
and 164.5 nM consistent with previous 
measurements (2).  Surprisingly, the entire set of 
mutant MBLs bound to MASP-2A with similar 
affinities and kinetics (Table I), indicating that 
none of the changes perturbed MASP binding 
(Fig. 2).  We next examined their complement 
activities by monitoring MBL-dependent MASP-
2K autoactivation with mannose-Sepharose as an 
activating target (Fig. 3).  In the presence of the 
target, all mutant MBLs activated the MASP 
with comparable rates as wild-type (t
1
/2 ~20 
mins).  The greatest difference observed was for 
the double-deletion mutant, which activated the 
MASP just two-fold more slowly (t
1
/2 ~40 mins), 
despite removal of six amino acid residues from 
the collagenous domain.  In the absence of the 
target, activation was relatively slow and similar 
to autoactivation by MASP-2 alone (>1000 min), 
indicating that all MBLs only activate on a 
carbohydrate target.  Thus, neither insertions, 
deletions nor removal of the kink-like region 
disrupt MASP-2 binding or activation, despite 
large changes to the position and relative 
orientations of the MASP-binding sites.  The 
tolerance of MBL to these changes must reflect 
significant adjustment and realignment of the 
collagenous stalks.  Given that collagenous 
domains themselves are relatively rigid and 
inflexible, changes must occur at the N-terminus 
where the stalks converge, probably at the 
junction between the cysteine-rich domain and 
the collagenous domain. 
 
Engineering Complement Activity into a 
Pulmonary-surfactant Protein Given its 
surprising tolerance to even large changes in 
MBL structure, we sought to further characterize 
MASP activation by engineering novel activity 
into a bouquet-like template.  We chose SP-A for 
these studies because of its similar structure, but 
lack of innate complement activity.  SP-A, like 
MBL, is a member of the collectin family of 
animal lectins with an N-terminal collagen-like 
domain and a C-terminal CRD (26).  It has 
similar sugar specificity to MBL (but with a 
preference for L-fucose over mannose (27)), 
allowing purification by affinity chromatography 
and assessment of complement activity using 
similar activation assays.  Although structurally 
analogous to MBL, the collagenous domains of 
SP-A and MBL are of different lengths and share 
no apparent sequence identity (other than the 
repeating Gly-Xaa-Yaa motif characteristic of all 
collagens; Fig. 4).  SP-A possesses a natural kink 
near the middle of the collagenous domain where 
the collagenous stalks splay apart, similar to 
C1q.  Previous studies have shown that upon 
removal of the kink, the stalks diverge nearer the 
N-terminus of polypeptides, at the junction 
between the N-terminal domain and the 
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collagenous domain, thus becoming more similar 
to MBL and ficolins (28).   
Three new recombinant constructs were 
created in which all or part of the MASP-binding 
motif was introduced into the collagenous 
domain of SP-A (Fig. 4).  Changes were made 
five Gly-Xaa-Yaa triplets towards the C-terminal 
side of the kink, to ensure that there would be 
enough space for the MASP to bind within the 
SP-A bouquet.  In SPA-KL, Glu63 and Cys64 
were replaced by lysine and leucine residues, 
respectively.  Lysine in the Xaa position is 
known to be essential for MASP binding and 
complement activation in both MBLs and 
ficolins.  The adjacent cysteine residue was also 
replaced to avoid any potential disulfide bond 
formation which might interfere with MASP 
binding.  In SPA-KLP a proline residue was 
introduced in place of the glutamate at position 
66 to further optimize the MASP-binding motif: 
Hyp-Gly-Lys-Leu-Gly-Pro.  One further change 
was made in SPA-KLPO, replacing Lys67 by a 
hydroxyproline residue.  Lysine residues in the 
Yaa position of collagen are often hydroxylated 
and glycosylated during biosynthesis, so this 
change was designed to prevent any potential 
steric inhibition of MASP binding by the sugar 
residues (23).  We created two further variants of 
SPA-KLPO, in which the kink was removed or 
modified to change the point at which the stalks 
splay apart (28), and thus more resemble MBL 
and ficolins.  In one mutant, SPA-KLPOdel the 
kink sequence (PCPP) was removed completely, 
and in the other, called SPA-KLPOS, the 
cysteine residue was replaced by a serine residue 
to remove the potential for disulfide bond 
formation, which is believed to tether the 
separate stalks together in native SP-A (28). 
Following production in chinese hamster 
ovary cells, all proteins bound to mannose- or 
fucose-Sepharose columns, demonstrating that 
they were correctly folded.  As expected, wild-
type SP-A did not bind to MASP-2A at any of 
the concentrations tested (up to 1 M).  
Surprisingly however, SPA-KL bound with 
appreciable affinity (Fig. 5).  The data best fitted 
a two-complex, parallel-reaction model, with 
apparent dissociation constants KD1
 
and KD2 of 
600 and 2120 nM respectively, compared to 3.8 
and 166 nM for MBL-MASP (Table 2).  SPA-
KLP bound with even higher affinity, with KDs 
of 36 and 104 nM, only slightly weaker than 
MBL.  Additional changes had little effect on 
MASP binding, so the naturally occurring lysine 
residue in SP-A (or its potential glycosylated 
derivative) does not prevent MASP access.  
Removal of the kink region also had little effect, 
indicating that the point at which the stalks splay 
apart and thus the angle between adjacent stalks 
is not limiting for MASP binding.  Thus, just 
three amino acid changes to the collagenous 
domain are sufficient to introduce MASP binding 
to SP-A almost comparable to MBL itself. 
We next examined if the modified SP-As 
could activate MASP-2K.  The half-time for 
activation by MBL was ~50 mins, using fucose-
Sepharose as a target.   As expected, wild type 
SP-A, which does not bind to the MASP at all 
and SPA-KL, which binds only weakly, did not 
activate the MASP (Fig. 6).  In each case the 
measured rate was similar to the intrinsic 
autoactivation rate of MASP-2K alone (t
1
/2 
>1000 min).  Surprisingly however, SPA-KLP 
and SPA-KLPO activated the MASP 
significantly faster than the basal rate (t
1
/2 ~260 
min).  Similar rates were also measured for SPA-
KLPOdel and SPA-KLPOS, demonstrating that 
the kink is neither necessary for MASP 
activation, nor modulates the rate of activation 
significantly.  To determine whether activation 
was target dependent, assays were repeated in the 
absence of fucose-Sepharose.  Surprisingly, 
comparable rates were observed (Fig. 7).  
Activation was still much faster than the basal 
rate, so must be driven by SP-A binding, but was 
constitutive occurring even in the absence of a 
carbohydrate target.  Thus, modified SP-As lack 
the control mechanisms required to activate 
MASP selectively. 
 
DISCUSSION 
 
The data presented here reveal that novel 
MASP-binding and complement activation can 
be introduced into a bouquet-like template 
through relatively minor changes to the chemical 
make-up of the collagenous stalks.  Just three 
substitutions: Glu63 to Lys, Cys64 to Leu and 
Glu66 to Pro, establish MASP binding in SP-A, 
which is almost equivalent to that of MBL.  Of 
these residues, only the lysine is essential for 
binding (10, 13).  Generally, the adjacent residue 
in the Yaa position (leucine in rat MBL and the 
SP-A mutants) has an aliphatic side chain, 
although a small polar residue such as serine can 
also be accommodated, but glutamate cannot 
(10).  The proline residue in the Xaa position of 
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the next Gly-Xaa-Yaa triplet is also not essential 
for MASP binding and can be replaced by an 
alanine with only a small decrease in affinity.  
The main function of the proline is probably to 
help stabilize the binding region (10).  It is 
notable that a significant component of the 
difference in MASP binding by SPA-KLP 
relative to SPA-KL is due to faster association, 
so probably reflects removal of the unfavourable 
electrostatic interactions mediated by the 
glutamate, rather than the introduction of the 
proline residue itself.  The presence of any 
additional binding sites for MASP on MBL can 
be completely ruled out from the data presented 
here.  Overall therefore, specificity of the MBL-
MASP interaction appears to be driven mainly 
by a single lysine residue in the collagen-like 
domain. 
Several other binding motifs have been 
identified in collagens and typically extend 
across two or more Gly-Xaa-Yaa triplets.  For 
example, the I domain of α2 integrin, recognizes 
the sequence GFOGER (29) and the extracellular 
matrix protein SPARC binds to the sequence 
GVMGFO (30).  Thus, the less stringent binding 
requirements of MASP-2 are relatively unusual.  
Nevertheless, it is notable that almost all of the 
other lysine residues in the collagenous domains 
of MBL and ficolins are in the Yaa position of 
the Gly-Xaa-Yaa repeat, so are likely to be post-
translationally modified by hydroxylation and 
glycosylation, which probably blocks any 
potentially incorrect MASP interactions.  
Perhaps even more importantly, MASP binds to 
MBL and ficolins through multiple relatively 
weak interactions involving up to four separate 
CUB-collagen contacts.  Thus, much of the 
binding specificity is probably mediated through 
the architectures of the subcomponents and the 
multivalent nature of the interactions.   
Complement activation is thought to be 
triggered by changes in the angle between 
collagenous stalks when complexes bind to an 
activating target (3, 31).  The data presented here 
indicate that significant conformational and 
rotational flexibility of the stalks must be 
permitted, implying that unbound MBL is 
probably quite flexible.  Both relaxed-to-strained 
and strained-to-relaxed mechanisms could 
explain the activation process.  The traditional 
view is that complexes circulate in an inactive 
zymogen form and distort upon binding to a 
target, and the changes to the structure of MBL 
are transmitted to the MASP to drive 
autoactivation.  However, in an alternative but 
equally valid possibility, binding of the zymogen 
MASP to MBL (or ficolin) induces strain into 
circulating complexes, which is released on 
pathogen binding to trigger activation.  A major 
difference between these mechanisms is that the 
relaxed or default states of the complexes would 
differ: inactive in a relaxed-to-strained 
mechanism, but active in a strained-to-relaxed 
mechanism.  In the work described here, MASP-
binding leads to constitutive activation by SP-A, 
even in the absence of a target.  Thus, activation 
is the default state, as would be expected in a 
strained-to-relaxed mechanism.  The possibility 
that modified SP-As are locked into a high 
energy conformation that activates MASP 
constitutively cannot be completely excluded.  
However, SP-A must also be flexible to bind to 
the MASP multivalently, which would seem to 
be at odds with this possibility.  Furthermore, 
large structural changes (through removal of the 
kink) do not affect MASP activation by SP-A, 
which also seems incompatible with such a 
mechanism. 
Based on these data, we propose that 
MBL-MASPs also activate via a strained-to-
relaxed mechanism.  We have recently suggested 
that activation of the C1 complex also operates in 
this way (2) and have proposed that strain is 
induced into the zymogen complex through the 
interactions between the protease domains of 
C1r.  In this respect, the mechanism must differ 
in MBL-MASP complexes because the SP 
domains of a MASP dimer do not interact 
significantly until the moment of autocatalysis.  
Interestingly however, recent analysis suggests 
that the MBL stalks are not evenly distributed, 
but rather are highly asymmetrical and separated 
by ~35–40° between nearest neighbours (32).  In 
this case, significant strain would be induced 
when MBL binds to a MASP.  Release of this 
strain upon target recognition might drive the 
changes that initiate complement activation. 
From an evolutionary perspective, these 
data suggest that recognition-mediated 
complement activation could have arisen 
relatively rapidly in a collectin-like molecule 
such as SP-A, as result of a small number of 
changes to the collagen-like domain.  It would 
also explain how similar activation mechanisms 
could have arisen multiple times in structurally 
analogous, but unrelated recognition 
components.  Clearly however, regulation of 
activation necessitates additional sequences, and 
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we are currently undertaking studies to identify these regions in MBL and ficolins. 
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Table I Kinetic properties of modified MBLs 
 kon (x10
4
) 
(M
-1
s
-1
) 
koff (x10
-3
) 
(s
-1
) 
KD
a 
(nM) 
Half-time for MASP 
activation 
(min) 
MBL 40 ± 1 
2.9 ± 0.1 
1.5 ± 0.1 
4.75 ± 0.1 
3.7 ± 0.1 
165 ± 2 
20 ± 1 
Deletion 38 ± 4 
3.1 ± 0.7 
3.8 ± 1.7 
5.4 ± 1.3 
11 ± 6 
175 ± 2 
22 ± 1 
Double 
deletion 
39 ± 1 
3.3 ± 0 
3.1 ± 0.1 
6.4 ± 0.1 
8.2 ± 0.3 
195 ± 3 
39 ± 3 
Insertion 44 ± 3 
4.6 ± 0 
2.2 ± 0.6 
9.1 ± 0.2 
4.9 ± 1.2 
199 ± 5 
21 ± 1 
Hinge 57 ± 1 
5.2 ± 0.2 
6.2 ± 2.7 
6.3 ± 0.2 
10 ± 2 
136 ± 9 
21 ± 1 
a
KD values were calculated from koff/kon for each experiment and were averaged from two separate 
experiments 
 
Table II Kinetic properties of engineered SP-As 
 kon (x10
-4
) 
(M
-1
s
-1
) 
koff (x10
3
) 
(s
-1
) 
KD
a 
(nM) 
Half-time for MASP 
activation
c
 
(min) 
SP-A N.B
b
 N.B
b
 N.B
b
 >1000
d
 
SPA-KL 1.2 ± 0.2 
4.3 ± 0.1 
7.0 ± 0.1 
91 ± 2 
600 ± 110 
2120 ± 100 
>1000
d
 
SPA-KLP 5.4 ± 2.9 
36 ± 24 
1.4 ± 0.1 
17.6 ± 1.0 
36 ± 20 
104 ± 77 
270 ± 56 
SPA-
KLPO 
2.6 ± 0.8 
9.6 ± 1.0 
2.5 ± 0.6 
22 ± 3.1 
97 ± 7 
232 ± 9 
256 ± 96 
SPA-
KLPOdel 
5.3 ± 2.3 
18 ± 0.0 
1.7 ± 0.1 
21 ± 1 
29 ± 17 
114 ± 2 
 316 ± 171 
SPA-
KLPOS 
4.5 ± 2.6 
21 ± 2 
4.6 ± 1.2 
37 ± 15 
99 ± 18 
203 ± 31 
166 ± 43 
a
KD values were calculated from koff/kon for each experiment and were averaged from two separate 
experiments 
b
No binding detected 
c
data from three separate experiments 
d
activation occurred a rate similar to autoactivation of MASP-2 alone  
 
Figure Legends 
 
FIGURE 1.  Changes to the collagenous domains of MBLs.  A, Domain organisations of MBL, 
ficolins and C1q.  The position of the kink or kink-like region is marked by 
an asterisk.  The location of the binding sites for MASPs or C1r/C1s on the collagenous domains are 
shown in light grey.  The recognition domains are: carbohydrate-recognition domain, fibrinogen-like 
domain and C1q-globular domain, respectively.  B, Aligned sequences of the collagenous domains of 
wild-type and modified MBLs.  Residues of the protease-binding motif are shown in light blue and 
the motif is shaded in light grey.  The GQ residues that form the kink-like region are boxed and shown 
in blue.  Residues inserted into the collagenous domain are shown in red.  Glycosylated hydroxylysine 
residues are underlined.  C, Predicted changes to the alignment of the MASP-binding sites on MBL 
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subunits as a result of a single insertion or deletion of a Gly-Xaa-Yaa into the collagenous domain 
based upon a pitch of 3.5 for a collagen helix.  The figure shows a cross-section through the four 
collagenous stalks, which are represented by circles.  Each binding site is shaded in light grey.  The 
structure of the CUB1-EGF-CUB2 domains of MASP-2 is from (14).  D, Schematic representation of 
the effects of changes to the position of the MASP-binding sites on MBL.  Only two MBL stalks are 
shown for clarity.  The MASP is shown as a box and is shaded in light grey.  CRDs are represented as 
grey circles.  The arrow shows the position of the insertion/deletion.  To accommodate the MASP, the 
collagenous stalks would have to move closer together for an insertion or splay further apart for a 
deletion. 
 
FIGURE 2.  MASP-binding by modified MBLs.  A, SDS polyacrylamide gel electrophoresis of 
wild-type and mutant MBLs under reducing (left) and non-reducing conditions (right).  Mutant MBLs 
are assembled from single polypeptides chains, which migrate as a ladder of covalently-linked 
polypeptides under non-reducing conditions, characteristic of the heterogeneous nature of oligomers 
of wild-type MBL (9).  B, Binding of MASP-2 to immobilised MBLs by surface plasmon resonance.  
MASP-2 was injected at 333, 167, 83, 42 nM over immobilized MBL (~7000 response units).  All 
data were fitted to a two-complex parallel binding model and the fits are shown by the dotted lines. 
 
FIGURE 3.  MASP activation by modified MBLs.  Kinetics of MBL-MASP-2 activation analyzed 
by SDS polyacrylamide gel electrophoresis.  A and B, wild-type MBL and the deletion mutant were 
incubated with MASP-2K together with mannose-Sepharose as an activating target.  Proteins were 
separated on a 4–12% linear gradient gel under reducing conditions and were stained with Coomassie 
blue. The N-terminal fragment of MASP-2K runs as a double band due to differential glycosylation. 
MASP activation was measured by quantifying cleavage of the MASP polypeptide.  B, Comparison of 
MASP-2K activation by wild-type and mutant MBLs. 
 
FIGURE 4.  Design of modified SP-As.  Sequences of the collagenous domains of MBL (top) and 
SP-A (bottom) Sequences were crudely aligned based on the positions of the kink of SP-A and the 
kink-like region of MBL (boxed).  The MASP-binding motif is shaded light grey.  Changes to the 
sequence of SP-A are indicated. 
 
FIGURE 5.  MASP-binding by modified SP-As.  Binding of MASP-2 to immobilised SP-As by 
surface plasmon resonance.  MASP-2 was injected at 764, 447, 261, 152 and 89 nM over each of the 
immobilized SP-As (~6000 response units).  All data were fitted to a two-complex parallel binding 
model and the fits are shown by the dotted lines. 
 
FIGURE 6.  MASP-2 activation by modified SP-As.  Assays fucose-Sepharose was used as the 
activating ligand.  Proteins were separated on a 15% SDS polyacrylamide gel and were stained with 
Coomassie blue.  B, MASP-2K activation by wild-type and mutant SP-As.  Averaged data from three 
separate experiments are shown.   
 
 
